Chandel Abhimanyu, Verster Alison, Rahim Husna, Khangoora Vikramjit, Nathan Steven D, Ahmad Kareem, Aryal Shambhu, Bagnola Aaron, Singhal Anju, Brown A Whitney, Shlobin Oksana A, King Christopher S
Department of Pulmonology and Critical Care, Walter Reed National Military Medical Center, Bethesda, MD, USA.
Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Pulm Circ. 2021 Apr 28;11(2):20458940211012366. doi: 10.1177/20458940211012366. eCollection 2021 Apr-Jun.
It has been suggested pleural effusions may develop in right heart failure in the absence of left heart disease. The incidence and prognostic significance of pleural effusions in pulmonary arterial hypertension is uncertain. Patients with pulmonary arterial hypertension followed at our tertiary care center were reviewed. Survival was examined based on the subsequent development of a pleural effusion. A total of 191 patients with pulmonary arterial hypertension met the inclusion criteria. The prevalence of pleural effusions on initial assessment was 7.3%. Among patients without a pleural effusion on initial imaging and at least one follow-up computerized tomography ( = 142), pleural effusion developed in 27.5% ( = 39) of patients. No alternative etiology of the effusion was identified in 19 (48.7%) cases and effusions deemed related to pulmonary arterial hypertension occurred at an incident rate of 38.6 cases per 1000 person-years. Of these, 14 (73.7%) were bilateral, 3 (15.8%) were right-sided, and 2 (10.5%) were left-sided. Effusion size was trace or small in 18 patients (94.7%). Development of a new pleural effusion was associated with attenuated survival in unadjusted survival analysis (HR: 3.80; 95% CI: 1.55-9.31), multivariate analysis (HR: 5.13; 95% CI: 1.86-14.16), and after the multivariate model was adjusted for concomitant pericardial effusion (HR: 4.86; 95% CI: 1.51-15.71). Negative impact on survival remained unchanged when effusions more likely related to an alternative cause were removed from analysis. In conclusion, pleural effusions can complicate pulmonary arterial hypertension in the absence of left heart disease. These effusions are frequently small in size, bilateral in location, and their presence is associated with decreased survival. Attenuated survival appears independent of the risk associated with a new pericardial effusion.
有人提出,在没有左心疾病的情况下,右心衰竭可能会出现胸腔积液。肺动脉高压患者胸腔积液的发生率及预后意义尚不确定。我们对在三级医疗中心接受随访的肺动脉高压患者进行了回顾性研究。根据随后胸腔积液的发生情况对生存率进行了分析。共有191例肺动脉高压患者符合纳入标准。初次评估时胸腔积液的患病率为7.3%。在初次影像学检查时无胸腔积液且至少接受过一次随访计算机断层扫描的患者中(n = 142),27.5%(n = 39)的患者出现了胸腔积液。19例(48.7%)病例未发现积液的其他病因,与肺动脉高压相关的积液发生率为每1000人年38.6例。其中,14例(73.7%)为双侧,3例(15.8%)为右侧,2例(10.5%)为左侧。18例患者(94.7%)的积液量为微量或少量。在未调整的生存分析中,新出现的胸腔积液与生存率降低相关(HR:3.80;95%CI:1.55 - 9.31),多因素分析中(HR:5.13;95%CI:1.86 - 14.16),在多因素模型针对合并心包积液进行调整后(HR:4.86;95%CI:1.51 - 15.71)。当从分析中排除更可能与其他病因相关的积液时,对生存的负面影响保持不变。总之,在没有左心疾病的情况下,胸腔积液会使肺动脉高压病情复杂化。这些积液通常体积较小,双侧出现,且其存在与生存率降低相关。生存率降低似乎与新出现的心包积液相关风险无关。